Device Trial Radar · NCT04233203
Faster Aspart on Insulin-pump Treated T1DM Patients
Last checked: Nov 19, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jan 31, 2020
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- Jesús Moreno FernándezAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Castilla-La Mancha
- First posted
- Jan 18, 2020
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Observational retrospective study about effectiveness and safety of insulin Faster Aspart on continuous subcutaneous insulin infusion treated adult Type 1 Diabetes Mellitus (T1DM) patients in routine clinical practice.
Conditions
- Type 1 Diabetes
Interventions
Insulin Faster AspartDrug
Currently receiving Faster Aspart during 3 or more months.
Insulin pumpDevice
Currently receiving CSII therapy during 6 or more months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MAGETime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Obispo Rafael Torija, St.
Ciudad Real, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.